%0 Journal Article %1 NordenZfoni.2007 %A Norden-Zfoni, Anat %A Desai, Jayesh %A Manola, Judith %A Beaudry, Paul %A Force, Jeremy %A Maki, Robert %A Folkman, Judah %A Bello, Carlo %A Baum, Charles %A DePrimo, Sam E. %A Shalinsky, David R. %A Demetri, Goerge D. %A Heymach, John V. %D 2007 %J Clin Cancer Res %K Cells Endothelial Monocytes Population SU11248 Tyrosine cells identify %N 9 %P 2643-2650 %T Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor %U http://clincancerres.aacrjournals.org/cgi/content/abstract/13/9/2643 %V 13 %X Purpose: There is an unmet need for noninvasive markers to measure the biological effects of targeted agents, particularly those inhibiting the vascular endothelial growth factor (VEGF) receptor (VEGFR) pathway, and identify patients most likely to benefit from treatment. In this study, we investigated potential blood-based biomarkers for SU11248 (sunitinib malate), a multitargeted tyrosine kinase inhibitor, in patients with metastatic imatinib-refractory gastrointestinal stromal tumors. Experimental Design: Patients (n = 73) enrolled in a phase I/II trial received SU11248 daily for 14 or 28 days followed by 14 days without treatment per cycle. Clinical benefit was defined as progression-free survival of >6 months. We assessed plasma markers, including VEGF and soluble VEGFR-2 (sVEGFR-2), and two cellular populations bearing VEGF receptors: monocytes and, in a subset of patients, mature circulating endothelial cells (CEC). Results: Compared to patients with progressive disease, patient

@article{NordenZfoni.2007, abstract = {Purpose: There is an unmet need for noninvasive markers to measure the biological effects of targeted agents, particularly those inhibiting the vascular endothelial growth factor (VEGF) receptor (VEGFR) pathway, and identify patients most likely to benefit from treatment. In this study, we investigated potential blood-based biomarkers for SU11248 (sunitinib malate), a multitargeted tyrosine kinase inhibitor, in patients with metastatic imatinib-refractory gastrointestinal stromal tumors. Experimental Design: Patients (n = 73) enrolled in a phase I/II trial received SU11248 daily for 14 or 28 days followed by 14 days without treatment per cycle. Clinical benefit was defined as progression-free survival of >6 months. We assessed plasma markers, including VEGF and soluble VEGFR-2 (sVEGFR-2), and two cellular populations bearing VEGF receptors: monocytes and, in a subset of patients, mature circulating endothelial cells (CEC). Results: Compared to patients with progressive disease, patient}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Norden-Zfoni, Anat and Desai, Jayesh and Manola, Judith and Beaudry, Paul and Force, Jeremy and Maki, Robert and Folkman, Judah and Bello, Carlo and Baum, Charles and DePrimo, Sam E. and Shalinsky, David R. and Demetri, Goerge D. and Heymach, John V.}, biburl = {https://www.bibsonomy.org/bibtex/2f8621c86345a8b8fe2693fc3e8855cee/kanefendt}, interhash = {790f5c227058d8c1212c88fac303dad2}, intrahash = {f8621c86345a8b8fe2693fc3e8855cee}, journal = {Clin Cancer Res}, keywords = {Cells Endothelial Monocytes Population SU11248 Tyrosine cells identify}, number = 9, pages = {2643-2650}, timestamp = {2010-02-05T11:28:56.000+0100}, title = {Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor}, url = {http://clincancerres.aacrjournals.org/cgi/content/abstract/13/9/2643}, volume = 13, year = 2007 }